Menu +

Tag: pfizer

Pfizer and BioNTech Announce New England Journal of Medicine Publication of Phase 1 Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that preliminary, peer-reviewed data from the Phase 1 portion of their ongoing U.S. study of BNT162b2 were published online in the New England Journal of Medicine (NEJM).   BNT162b2, which has advanced into a global Phase 3 study, is part of the companies’ mRNA-based […]

BioNTech and Pfizer Announce Nature Publication of German Phase 1/2 Study Data from mRNA-based Vaccine Candidate BNT162b1 Against SARS-CoV-2

BioNTech SE (Nasdaq: BNTX) and Pfizer Inc. (NYSE: PFE) today announced that preliminary, peer-reviewed data from their ongoing German Phase 1/2 Study of BNT162b1 were published online in the journal Nature. BNT162b1 is part of the companies’ mRNA-based vaccine development program Lightspeed against SARS-CoV-2. The preliminary clinical data from the German study of BNT162b1, a […]

Pneumococcal Vaccine Prevenar 13 from Pfizer Labelled in English Available in Germany

On 12 March 2020, the Paul-Ehrlich-Institut informed the public on supply problems with pneumococcal vaccines on its website. English labelled Prevenar 13 will be commercially available, as from 28 April 2020. These doses will supplement the regular deliveries. The importation of the product was supported by a permission pursuant to Section 79 (5) German Drug […]